about
Regulation of TOR by small GTPasesSirtuin 1 and aging theory for chronic obstructive pulmonary diseaseMilk--A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent TranslationTargeting the intragraft microenvironment and the development of chronic allograft rejectionThe search for antiaging interventions: from elixirs to fasting regimensRapalogs in cancer prevention: anti-aging or anticancer?mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic InterventionsAn autism case history to review the systematic analysis of large-scale data to refine the diagnosis and treatment of neuropsychiatric disordersGenome-wide analysis of miRNA signature in the APPswe/PS1ΔE9 mouse model of alzheimer's diseaseArchitecture of human mTOR complex 1The histone H3 lysine 56 acetylation pathway is regulated by target of rapamycin (TOR) signaling and functions directly in ribosomal RNA biogenesisCancer stem cell metabolism: a potential target for cancer therapyIncreased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expressionWhere is mTOR and what is it doing there?Reactive oxygen species a double-edged sword for mesotheliomaSuppression of replicative senescence by rapamycin in rodent embryonic cellsIncreased 4E-BP1 Expression Protects against Diet-Induced Obesity and Insulin Resistance in Male Mice.Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.Rapamycin increases mitochondrial efficiency by mtDNA-dependent reprogramming of mitochondrial metabolism in Drosophila.Moderate lifelong overexpression of tuberous sclerosis complex 1 (TSC1) improves health and survival in miceDownregulation of MicroRNA-193b-3p Promotes Autophagy and Cell Survival by Targeting TSC1/mTOR Signaling in NSC-34 Cells.A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors.Extraoral Taste Receptor Discovery: New Light on Ayurvedic Pharmacology.Regulation of blood-testis barrier (BTB) dynamics during spermatogenesis via the "Yin" and "Yang" effects of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2.Ras transformation uncouples the kinesin-coordinated cellular nutrient responseConvergence of ubiquitylation and phosphorylation signaling in rapamycin-treated yeast cells.Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21.An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.TORC2-a new player in genome stabilitymTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3Tissue-specific responses of IGF-1/insulin and mTOR signaling in calorie restricted rats.Aging and energetics' 'Top 40' future research opportunities 2010-2013.Aurora kinase a suppresses metabolic stress-induced autophagic cell death by activating mTOR signaling in breast cancer cellsSelective anti-cancer agents as anti-aging drugsIntegrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitorsRegulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell linesAn mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease
P2860
Q24598385-30C2FC5A-53D8-4681-96C1-76F0A291980BQ26799889-CBE83887-7F20-4F39-833F-C09786127A77Q26801523-AE8DF585-FCF5-4FC8-9363-95E7256CAB84Q26852762-DFE19F3E-0127-46E0-95AE-049BAD14D757Q26863497-68940EB0-5A8A-4EBA-89CF-F8D8F4CC7EA8Q26866151-1FEB9DF6-A721-4CF4-A30D-797A142D4928Q27007511-18D4DAC6-4E5B-4634-B39E-14DD284E8054Q27008961-23AEFBC4-7C69-4156-8442-7683C75D2BF0Q27320372-485108A2-AFD8-4CBC-8CDF-2FB3320A4C24Q27703146-4720B778-2936-4971-A9E3-2A76F6A835CEQ27936099-10C051BD-01F1-4B63-B7D0-88AF31D53C87Q28079045-48342F88-8B3D-4D7B-A2C6-4B71CB1C6AD8Q28297737-24E150D9-4E7C-4FFE-9E11-EF74855D75FDQ28305068-C29C596B-770D-4AF2-B6D0-24CEC30ECF5EQ28392665-63EA187B-151C-45C9-B72C-C8F3C0E34F56Q28571864-4F46F5E7-85A5-4299-ABD4-82E175BDA1CAQ30391587-8380F4F9-BCB1-4CDE-843A-2A712AF97C2BQ30533934-4BA38CD5-28C3-4FA5-877E-B7C6AE634B8FQ30833513-7A43DBEB-3BEB-41A7-8E5F-0519411962D3Q33429430-30F764BA-F322-494F-A846-8559F2ECEB68Q33442621-6C178FD0-76C7-4D78-B844-BA29E9D21D22Q33613363-FC4521C9-E6CA-4E29-9B16-260AD0A4EA77Q33678212-C713A2A4-C3ED-4D99-A230-40A276CFB055Q33736536-758256F2-EB66-4434-B0BF-71F331EBA70FQ33764533-A2CF3D97-AF0E-4ACB-B0F9-05F6F9FDC1ADQ33794932-4D8272BB-643B-4259-B469-E8FE09B8F8AFQ33863571-5DFBAAFD-D899-4ED6-9C70-8736EACE06DFQ33972110-3B930B1A-5AF0-4EDC-BEB1-A21E37C8D5D1Q34018045-91DF900A-9975-48FD-8948-FFD8515F7D48Q34060841-43508683-1559-4438-A8A4-7E0E0064E4CEQ34074513-79F74F4D-1FCA-44B9-AB95-2E6CA21C2FAAQ34131149-38B50250-A098-4AE9-99CE-A61358559BE5Q34231591-575D8581-36D8-4E86-91F1-03ECF7D584C8Q34305775-CAB017C0-4481-4284-85DE-6D36103173ABQ34341924-FFE5533F-C613-4C4D-82E2-5E2D251D54C3Q34365747-23ECC02D-ED59-4442-833A-8D33A38B12D5Q34392470-6C113AA2-C64D-4CE1-89D6-881B3D4B72F6Q34576589-EA9FE8BD-06BD-46BF-9043-F4B57923C1B1Q34673267-1F5003F0-DE55-442D-9C2F-07D95B576838Q34865335-796576FE-1565-4E9E-B85C-D481BC288FCC
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
mTOR signaling in disease.
@en
mTOR signaling in disease.
@nl
type
label
mTOR signaling in disease.
@en
mTOR signaling in disease.
@nl
prefLabel
mTOR signaling in disease.
@en
mTOR signaling in disease.
@nl
P1476
mTOR signaling in disease.
@en
P2093
Eva Dazert
Michael N Hall
P304
P356
10.1016/J.CEB.2011.09.003
P577
2011-09-29T00:00:00Z